	US 12,240,914 B2
	Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof
Shaoxiong Wang, Shanghai (CN); Juehua Xu, Shanghai (CN); Yunhua Zhou, Shanghai (CN); and Yongfeng Chen, Shanghai (CN)
Assigned to MAB-LEGEND BIOTECH CO., LTD., Shanghai (CN)
Appl. No. 17/423,426
Filed by MAB-LEGEND BIOTECH CO., LTD., Shanghai (CN)
PCT Filed Oct. 22, 2019, PCT No. PCT/CN2019/112412 § 371(c)(1), (2) Date Jul. 15, 2021, PCT Pub. No. WO2021/022676, PCT Pub. Date Feb. 11, 2021.
Claims priority of application No. 201910729990.5 (CN), filed on Aug. 8, 2019.
Prior Publication US 2022/0153872 A1, May 19, 2022
Int. Cl. C07K 16/00 (2006.01); A61P 7/02 (2006.01); C07K 16/36 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/36 (2013.01) [A61P 7/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

18 Claims

1. An antigen-binding fragment of an anti-Factor XIa antibody, said antibody comprising heavy chain and light chain variable regions, wherein complementarity determining regions (CDRs) of said heavy chain variable region comprises amino acid sequences having SEQ ID NOs: 1, 2, and 3; and CDRs of said light chain variable region comprises amino acid sequences having SEQ ID NOs: 4, 5, and 6.